The mycobacterial cell wall: Structure, biosynthesis and sites of drug action

Current Opinion in Chemical Biology

Volumn 1, Issue 4, 1997, Pages 579-588

  Chatterjee, Delphi ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORYNEBACTERINEAE;

ANTIINFECTIVE AGENT; ARABINOGALACTAN; GALACTAN; LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE; MYCOLIC ACID; PEPTIDOGLYCAN;

CARBOHYDRATE ANALYSIS; CELL WALL; CHEMISTRY; CONFORMATION; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR GENETICS; MYCOBACTERIOSIS; MYCOBACTERIUM; REVIEW; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CELL WALL; GALACTANS; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; MYCOLIC ACIDS; PEPTIDOGLYCAN;

EID: 0031315805     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80055-5     Document Type: Article

References (63)

1. Brennan PJ, Nikaido H: The envelope of mycobacteria. Annu Rev Biochem 1995, 64:29-63.
2. McNeil M: Targeted preclinical drug development for Mycobacterium avium complex: a biochemical approach. In Mycobacterium Avium Complex Infection. Edited by Korvick JA, Benson CA. New York: Marcel Dekker Inc; 1996:263-283.
3. 2 in the slow-growing species only points to a difference in the structure of the envelopes of rapid- and slow-growing species.
4. Aspinall GO, Chatterjee D, Brennan PJ: The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Adv Carbohydr Chem Biochem 1995, 51:169-242.
5. Ortalo-Magne A, Anderson AB, Daffé M: The outermost capsular arabinomannans and other mannoconjugates of virulent and avirulent tubercle bacilli. Microbiology 1996, 142:927-935.
6. Besra GS, Brennan, PJ: The mycobacterial cell envelope: a target for novel drugs against tuberculosis. J Pharm Pharmacol 1997, 49:25-30.
7. Lederer E: Cell walls of mycobacteria and related organisms, chemistry and immunostimulant properties. Mol Cell Biochem 1975, 7:87-104.
8. Petit JF, Adam A, Weitzerbin-Falszpan J, Lederer E, Ghuysen JM: Chemical structure of the cell wall of Mycobacterium smegmatis. I. Isolation and partial characterization of the peptidoglycan. Biochim Biophys Res Commun 1969, 35:478-483.
9. Weitzerbin-Falszpan J, Das BC, Azuma I, Adam A, Petit JF, Lederer E: Isolation and mass spectrometric identification of the peptide subunits of mycobacterial cell walls. Biochem Biophys Res Commun 1970, 40:57-63.
10. Schleifer KH, Kandler OB: Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 1972, 36:407-477.
11. Azuma IJ, Thomas DW, Adam A, Ghuysen JM, Bonaly R, Petit JF, Lederer E: Occurrence of N-glycolylmuramic acid in bacterial cell walls. Biochim Biophys Acta 1970, 20:444-451.
12. McNeil M, Daffé M, Brennan PJ: Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. J Biol Chem 1990, 265:18200-18206.
13. Lee RE, Brennan PJ, Besra GS: Mycobacterium tuberculosis cell envelope. Curr Top Microbiol Immunol 1996, 215:1-27.
14. 1H nuclear magnetic resonance spectroscopy. Biochemistry 1995, 34:4257-4266.
15. McNeil M, Daffé M, Brennan PJ: Location of the mycolyl ester substituents in the cell walls of mycobacteria. J Biol Chem 1991, 266:13217-13223.
16. Besra GS, Chatterjee D: Lipids and carbohydrates of Mycobacterium tuberculosis. In Tuberculosis: Pathogenesis, Protection, and Control. Edited by Bloom BR. Washington DC: American Society of Microbiology; 1996:285-306.
17. Goren MB, BrennanPJ: Mycobacterial lipids: chemistry and biological activities. In Tuberculosis, Edited by Youmans GP. Philadelphia: WB Saunders; 1979:69-193.
18. Yuan Y, Crane DC, Musser JM, Sreevatsan S, Barry CE: MMAS-I, the branch point between cis- and trans-cyclopropane-containing oxygenated mycolates in Mycobacterium tuberculosis. J Biol Chem 1997, 272:10041-10049.
19. Hunter SW, Gaylord H, Brennan PJ: Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. 1986, 261:12345-12351.
20. Hunter SW, Brennan PJ: Evidence for the presence of a phosphatidylinositol anchor on the lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. J Biol Chem 1990, 265:9272-9279.
21. Chatterjee D, Hunter SW, McNeil M, Brennan PJ: Lipoarabinomannan: multiglycosylated form of the mycobacterial mannosylphophatidylinositols. J Biol Chem 1992, 267:6228-6233.
22. Venisse A, Riviére M, Vercauteren J, Puzo G: Structural analysis of the mannan region of lipoarabinomannan from Mycobacterium bovis BCG. Heterogeneity in phosphorylation state. J Biol Chem 1995, 270:15012-15021.
23. Khoo K-H, Dell A, Morris HR, Brennan PJ, Chatterjee D: Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium. J Biol Chem 1995, 270:12380-12389.
24. Brennan PJ, Hunter SW, McNeil M, Chatterjee D, Daffé M: Reappraisal of the chemistry of mycobacterial cell walls, with a view to understandung the roles of individual entities in disease processes. In Microbial Determinants of Virulence and Host Response. Edited by Ayoub EM, Cassell GH, Branche WC Jr, Henry TJ. Washington DC: American Society for Microbiology; 1990:55-75.
25. Chatterjee D, Bozic CM, McNeil M, Brennan PJ: Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. J Biol Chem 1991, 266:9652-9660.
26. Chatterjee D, Lowell K, Rivoire B, McNeil M, Brennan PJ: Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains. J Biol Chem 1992, 267:6234-6239.
27. Prinzis S, Chatterjee D, Brennan PJ: Structure and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG. J Gen Microbiol 1993, 139:2649-2658.
28. Gilleron M, Himoudi N, Adam O, Constant P, Venisse A, Riviere M, Puzo G: Mycobacterium smegmatis phosphoinositolsglyceroarabinomannans. J Biol Chem 1997, 272:117-124.
29. Kaplan G, Gandhi RR, Weinstein DE, Levis, WR, Patarroyo ME, Brennan PJ, Cohn ZA: Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J Immunol 1987, 138:3028-3034.
30. Sibley LD, Hunter SW, Brennan PJ, Krahenbuhl JL: Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immunol 1988, 56:1232-1236.
31. Chan J, Fan X, Hunter SW, Brennan PJ, Bloom BR: Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immunol 1991, 59:1775-1761.
32. Barnes PF, Chatterjee D, Abrams JS, Lu S, Wang E, Yamamura, Brennan PJ, Modlin RL: Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan: relationship to chemical structure. J Immunol 1992, 149:541-547.
33. Chatterjee D, Roberts AD, Lowell K, Brennan PJ, Orme IM: Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect Immun 1992, 60:1249-1253.
34. Adams LB, Fukutomi Y, Krahenbuhl JL: Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence. Infect Immun 1993, 61:4173-4181.
35. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL: Tumor necrosis factor production in patients with leprosy. Infect Immun 1992, 60:1441-1446.
36. Roach TIA, Barton CH, Chatterjee D, Blackwell JM: Macrophage activation: Lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-α J Immunol 1993, 150:1886-1896.
37. Roach TIA, Barton CH, Chatterjee D, Liew FY, Blackwell JM: Opposing effects of Interferon- on iNOS and IL10 expression in LPS and mycobacterial LAM stimulated macrophages. Immunology 1995, 85:106-113.
38. Peterson PK, Hu SX, Sheng WS, Kravitz FH, Molitor TW, Chatlerjee D, Chao CC: Thalidomide inhibits tumor necrosis factor-α production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995, 172:1137-1140,.
39. Schlesinger LS: Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol 1993, 150:2920-2925.
40. Schlesinger LS, Kaufman TM, Iyer S, Hull SR, Marchiando LK: Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J Immunol 1996, 157:4568-4575.
41. Beckman EM, Melin A, Behar SM, Sieling PA, Chatterjee D, Furlong ST, Matsumoto R, Rosat JP, Modlin RL, Porcelli SA: CD1c restricts responses of mycobacteria-specific T cells - evidence for antigen presentation by a second member of the human CD1 family. J Immunol 1996, 157:2795-2803. Human CD1 has been shown to present microbial lipids and lipoglycans (LAM) and mycolic acids to T cells. T cell responses to these nonpeptide antigens should provide a strategic target for immunologic intervention in infectious disease.
42. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, Soriano T, Bloom BR, Brenner MB, Kronenberg M, Brennan PJ, Modlin RL: CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 1995, 269:227-230.
43. Wolucka BA, McNeil MR, de Hoffmann E, Chojnacki T, Brennan PJ: Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem 1994, 269:23328-23335.
44. Lee RE, Mikusova K, Brennan PJ, Besra GS: Synthesis of the mycobacterial arabinose donor-D-arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic arabinosyl-transferase assay and identification of ethambutol as an arabinosyl transferase inhibitor. J Am Chem Soc 1995, 117:11829-11832.
45. Yi Xin, Lee RE, Scherman MS, Khoo KH, Besra GS, Brennan PJ, McNeil M: Characterization of the in vitro synthesized arabinan of mycobacterial cell walls. Biochim Biophys Acta 1997, 1335:231-234.
46. Scherman MS, Bournonville LK, Bush D, Xin Y, Deng L, McNeil M: Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate. J Biol Chem 1996, 271:29652-29658. The biosynthetic pathway for the formation of polyprenylphosphate-ribose is reported in this important work. 5-phosphoribose pyrophosphate was is also found to be a precursor of polyprenylphosphate-arabinose (DPA) and the latter is formed via 5P-DPA.
47. Mikusov K, Mikus M, Besra GS, Hancock I, Brennan PJ: Biosynthesis of the linkage region of the mycobacterial cell wall. J Biol Chem 1996, 271:7820-7828. The first steps in the biosynthesis of the very complex mycobacterial cell wall are described in this paper. The work described involves the synthesis of the unique linker disaccharide (Figure 1) on a polyprenyl P-P- carrier (Figure 5) followed by the assembly of the galactan unit. Assays are also defined for screening of new anti-tuberculosis drugs active against cell wall synthesis.
48. Nassau PM, Martin SL, Brown RE, Weston A, Monsey D, McNeil M, Duncan K: Galactofuranose biosynthesis in Escherichia coli K12: Identification and cloning of UDP-galactopyranose mutase. J Bacteriol 1996, 178:1047-1052.
49. Brennan PJ, Ballou CE: Biosynthesis of mannophosphoinositides by Mycobacterium phlei. J Biol Chem 1967, 242:3046-3056.
50. Yokoyama K, Ballou CE: Synthesis of -1-6 mannooligosaccharide in M. smegmatis. J Biol Chem 1989, 264:21621-21628.
51. Besra GS, Morehouse CB, Rittner CM, Waechter CJ, Brennan PJ: Early steps in the biosynthesis of LAM. J Biol Chem 1997, 272:18460-18466. In this elegant study, origins of the mannose units of the PIMs and LM of mycobacterial lipoglycans have been described. In addition to this, a linear 16 linked linear mannan was also isolated and identified to be an apparent precursor of mature LM and LAM.
52. Lacave C, Laneelle MA, Laneelle G: Mycolic acid synthesis by Mycobacterium aurum cell-free extracts. Biochim Biophys Acta 1990, 1042:315-323.
53. Lee RE, Armour JW, Takayama K, Brennan PJ, Besra GS: Mycolic acid biosynthesis: definition and targeting of the Claisen condensation step. Biochim Biophys Acta 1997, 1346:275-284.
54. Besra GS, Sievert T, Lee RE, Slayden RA, Brennan PJ, Takayama K: Identification of the apparent carrier in mycolic acid synthesis. Proc Natl Acad Sci USA 1994, 91:12735-12739,
55. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997, 276:1420-1422. The antigen 85 complex was described previously as a major secreted protein of M. tuberculosis, implicated in disease pathogenesis through its fibronectin-binding capacities. This is the first evidence that describes the function of the protein as a mycolyltransferase involved in the final stages of cell wall assembly.
56. Winder FG: Mode of action of the antimycobacterial agent and associated aspects of the molecular biology of mycobacteria In The Biology of Mycobacteria, vol 1. Edited by Ratledge C, Stanford J. London: Academic Press; 1982:354-441.
57. Takayama K, Kilburn JO: Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989, 33:1493-1499.
58. Mikusov K, Slayden RA, Besra GS, Brennan PJ: Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrobial Agents Chemother 1995, 39:2484-2489.
59. 6 motif is an essential structural entity for a functional cell wall, and the biosynthetic machinery responsible for its synthesis is the effective target of Emb.
60. Belanger AE, Besra GS, Ford ME, Mikusov K, Belisle JT, Brennan PJ, Inamine JM: The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996, 93:11919-11924. The molecular mechanisms of drug action and drug resistance of the antimycobacterial compound, ethambutol (Emb), are unknown. In this novel study, cloning and sequencing strategy of the emb region that confers resistance to Emb when expressed in M. smegmatis is described. Evidence also points towards embA and embB genes that encode for arabinosyl transferase that is the primary target for Emb.
61. Zhang Y, Heym B, Allen B, Young D, Cole ST: The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
62. Banerjee A, Dubnau E, Quemard A, Balasubramanium V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263:227-230.
63. Mdluli K, Sherman DR, Mickey MJ, Kreiswirth BN, Morris S, Stover CK, Barry CE III: Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 1996, 174:1085-1090.